【摘要】 目的 :观察蚓激酶对缺血性脑血管病患者血液流变学及纤溶系统的影响及不良反应。方法 :采用多中心、双盲、安慰剂对照的方法治疗缺血性脑血管病恢复期的患者 2 85例。治疗组 2 0 9例予蚓激酶 430mg ,tid ;安慰剂组 76例服安慰剂 2粒 ,tid .疗程均为 4周。结果 :蚓激酶治疗可使血纤维蛋白原降低 (P <0 .0 1) ,部分患者(4 3.1%)D二聚体转为阳性 ,血小板聚集率降低 (P <0 .0 1)。对红细胞计数、血细胞比容、血小板计数也有轻度降低。不良反应发生率为 3.83%。结论 :蚓激酶可作为治疗和预防缺血性脑血管病的安全的药物之一。更多还原

【Abstract】 Objective:To investigate the effect on fibrinogen and D-dimmer as so as aggregation of platelet of lumbrokinase on patients with cerebral infarction.Methods:Multicentre,double-blind and placebo controlled study on 285 patients with cerebral infarction.The active group(n=209) received lumbrokinase 430mg,tid and the control group(n=76) received placebo for 4 weeks.Results:Fibrinogen,platelet aggregation were reduced after the treatment with lumbrokinase,D-dimmer were turned to positive in 43.1% patients.HCT,RBC and PLT were slightly reduced.The side effect was 3.83% for active group and 1.31% for control group.Conclusion:It suggested that lumbrokinase can serve as an effective and safe drug of preventing and treating ischemic cerebral vascular disease.更多还原